Eton Pharmaceuticals Inc (ETON)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Eton Pharmaceuticals Inc (ETON) Stock Forecast
Analysts expect Eton Pharmaceuticals (ETON) to earn $1.78 per share in the fiscal year ending Dec 31, 2026, on revenue of $179.91M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $3.31.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 86.0% and revenue estimates rise 59.5%.
- Fiscal year ending Dec 31, 2026
- $1.78
- EPS consensus, revenue $179.91M
- Fiscal year ending Dec 31, 2027
- $3.31
- EPS consensus, revenue $286.90M
- Next report
- Mar 17, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.78 | $1.68 to $1.87 | 2 | $179.91M | $178.10M to $182.00M | 4 |
| Dec 31, 2027 | $3.31 | $3.22 to $3.39 | 2 | $286.90M | $276.50M to $305.11M | 4 |
Quarterly Estimates
The EPS consensus rises from $0.43 for the quarter ending Dec 31, 2026 to $0.73 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.43 | $0.29 to $0.58 | 6 | $57.60M | $46.55M to $63.24M | 6 |
| Mar 31, 2027 | $0.73 | $0.73 to $0.73 | 1 | $65.00M | $63.50M to $66.50M | 2 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 69.5% from $1.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.78 | $1.40 | $1.40 | $1.40 | $1.05 | +69.0% |
| Fiscal year ending Dec 31, 2027 | $3.31 | $2.55 | $2.58 | $2.58 | $2.18 | +51.6% |
| Quarter ending Mar 31, 2027 | $0.73 | $0.45 | $0.47 | $0.47 | $0.36 | +102.8% |
Frequently Asked Questions About ETON
What is the ETON stock forecast?
Consensus analyst estimates put Eton Pharmaceuticals's EPS at $1.78 for the fiscal year ending Dec 31, 2026, on revenue of $179.91M. The consensus rating from 4 analysts is Buy.
How do analysts rate ETON stock?
Of 4 analysts covering Eton Pharmaceuticals, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ETON next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.78, with estimates from $1.68 to $1.87 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.31, with estimates from $3.22 to $3.39 from 2 analysts.
What revenue do analysts expect from Eton Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $179.91M, with estimates from $178.10M to $182.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $286.90M, with estimates from $276.50M to $305.11M.
How many analysts cover ETON?
4 analysts rate Eton Pharmaceuticals stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ETON pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors